Company / Accounts Receivable
OCULAR THERAPEUTIX, INC Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$30.6M
FY2025
5-year range
$21.1M / $32.4M
FY2021-FY2025
Trend
-5.4%
vs FY2024
Sector context
#82 of 115
Health Care
What the data says
At $31M, OCULAR THERAPEUTIX, INC's accounts receivable ranks #82 of 115 in the Health Care sector. Improved from $26M to $31M over the past 2 years.
Based on SEC 10-K filings.
$31M in FY2025 with a 5-year CAGR of +20.1%.
Improved from $26M to $31M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +12.9%
- 5-Year CAGR
- +20.1%
- 10-Year CAGR
- -
Sector benchmark
#82 of 115 in Health CareTop 71% of 115This company $30.6M Sector average $1.1B
▼
-97.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.1%, indicating consistent growth.
- In FY2025, accounts receivable decreased 5.4% year-over-year.
- Ranks #82 out of 115 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $30.6M | -5.4% |
| FY2024 | $32.4M | +23.7% |
| FY2023 | $26.2M | +22.8% |
| FY2022 | $21.3M | +0.9% |
| FY2021 | $21.1M | +72.5% |
| FY2020 | $12.3M | +380.8% |
| FY2019 | $2.5M | +1167.7% |
| FY2018 | $201.0K | -11.1% |
| FY2017 | $226.0K | -9.6% |
| FY2016 | $250.0K | +29.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026